BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, today announced that it will present clinical and scientific findings at key oncology conferences. According to the update, the company was selected to present a poster at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, to be held in San Francisco, California from February 28 to March 2, 2019. The poster will highlight findings related to the mechanism of action of BriaCell’s lead candidate, Bria-IMT(TM), as well as BriaDX(TM), the Bria-IMT(TM) companion diagnostic test and Bria-OTS(TM), the company’s off-the-shelf personalized immunotherapy. In addition, BriaCell Founder and Director Dr. Charles L. Wiseman will be featured as a keynote speaker at the 10th Euro Breast Cancer Summit to be held in Paris, France on March 20 – 21, 2019. The company has also been accepted to present a poster at the Annual Meeting for the American Association for Cancer Research (“AACR”) to be held at the Georgia World Congress Center in Atlanta, Georgia from March 29 – April 3, 2019. The poster will summarize molecular and clinical findings that support the advancement of the Bria-OTS(TM) program.
“An estimated 42,000 women will die of breast cancer in 2019 in the U.S. alone, indicating a substantial unmet medical need for a large patient population whose tumors had become resistant to chemotherapy or other therapeutic regimens,” BriaCell President and CEO Dr. Bill Williams stated in the news release. “Currently, there are no effective treatment options for these patients, leaving them with a very poor prognosis and a grim survival outlook. We are excited to share our findings with the scientific and medical community at ASCO-SITC Clinical Immuno-Oncology Symposium and the AACR meeting. We believe that our unique approach is promising and supports personalizing our immunotherapy to match individual patients. HLA typing may serve as a companion diagnostic test, BriaDX(TM), to determine the best match for Bria-IMT(TM) and for Bria-OTS(TM), our off-the-shelf personalized immunotherapy, which is under development for breast cancer patients. Bria-OTS(TM) has the potential to stimulate the immune system in a manner tailored to the patient without the complexities associated with other personalized therapies, to bring hope to advanced breast cancer patients with few effective treatment options. Further studies are merited and in progress, especially for our ongoing combination study of Bria-IMT(TM) with KEYTRUDA®.”
To view the full press release, visit http://nnw.fm/mYj4t
About BriaCell Therapeutics Corp.
BriaCell is an immuno-oncology-focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company]. The combination study is listed in ClinicalTrials.gov as NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS, which is expected to cover over 90 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense and complex manufacturing logistics associated with other personalized immunotherapies. For more information, visit the company’s website at www.BriaCell.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
